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Background
DNA vaccination is a promising technology, but the
reported immunogenicity in human trials is low. Here we
use optimized DNA vectors and intramuscular electropo-
ration procedures to show great increases in immuno-
genicity of DNA vaccines and protection from high
viremia after challenge.
Methods
Indian rhesus macaques were vaccinated intramuscularly
by EP with optimized DNA vectors producing the major-
ity of SIVmac239 proteins. Immune responses were mon-
itored by flow cytometry. Animals were challenged
rectally with high dose SIVmac521 and plasma viral loads
and immune responses were monitored.
Results
DNA delivery using EP led to greatly enhanced expression
of SIV antigens and increased cellular responses (up 3% of
total T cells) that were broad, long-lasting (up to 45 weeks
post vaccination) and included cells of multifunctional
phenotype. SIV-specific cellular responses were found
both in blood, BAL and rectal mucosa. Interestingly, com-
pared to blood, the responses in BAL were consistently
higher (up to 2 log) and included a higher frequency of
polyfunctional cells. The cellular responses were charac-
terized as predominantly EM CD4+ and CD8+ T cells in
BAL and as both CM and EM T cells in blood. EP DNA
delivery elicited both systemic and mucosal humoral
immune responses, including the induction of Gag-spe-
cific IgA. Upon high dose SIVmac251 challenge, the vacci-
nated animals showed statistically significant lower VL
peak in acute (1 log10) and in chronic viremia (1.7
log10).
Conclusion
The combination of optimized DNA vectors and
improved delivery by EP led to great induction of SIV-spe-
cific systemic and mucosal immune responses. DNA vac-
cination in the absence of any heterologous boost can
provide protection from high viremia comparable to any
other vaccine modality tested in this macaque model. The
immunological and virological benefit achieved in the
macaque model provides critical information to improve
DNA vaccination efficacy in humans.
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